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Abstract
Introduction: Observational studies suggest statin therapy reduces incident sepsis, but few studies have examined
the impact on new organ failure. We tested the hypothesis that statin therapy, administered for standard clinical
indications to ventilated intensive care unit patients, prevents acute organ failure without harming the liver.
Methods: We performed a retrospective, single-centre cohort study in a tertiary mixed medical/surgical intensive
care unit. Mechanically ventilated patients without nonrespiratory organ failure within 24 hours after admission
were assessed (during the first 15 days) for new acute organ failure (defined as Sequential Organ Failure
Assessment (SOFA) score 3 or 4), liver failure (defined as new hepatic SOFA ≥3, or a 1.5 times increase of bilirubin
from baseline to a value ≥20 mmol/l), and alanine transferase (ALT) > 165 IU/l. The effect of statin administration
was explored in generalised linear mixed models.
Results: A total of 1,397 patients were included. Two hundred and nineteen patients received a median (interquartile
range) of three (two, eight) statin doses. Patients receiving statins were older (67.4 vs. 55.5 years, P < 0.0001), less likely
female (25.1% vs. 37.9%, P = 0.0003) and sicker (Acute Physiology and Chronic Health Evaluation (APACHE) II score 20.3
vs. 17.8, P < 0.0001). Considering outcome events at least 1 day after statin administration, statin patients were equally
likely to develop acute organ failure (28.4% vs. 22.3%, P = 0.29) and hepatic failure (9.5% vs. 7.6%, P =0 . 3 4 ) ,b u tw e r e
more likely to experience an ALT increase to > 165 IU/l ((11.2% vs. 4.8%, P = 0.0005). Multivariable analysis showed that
APACHE II score (odds ratio (OR) = 1.05 per point; 95% confidence interval (CI) = 1.03 to 1.07) and APACHE II admission
category (P < 0.0001), but not statin administration (OR = 1.21; 95% CI = 0.92 to 1.62), were significantly associated with
acute organ failure occurring on or after the day of first statin administration. Statin administration was not associated
with liver impairment (OR = 1.08; 95% CI = 0.66 to 1.77) but was associated with a rise in ALT > 165 IU/l (OR = 2.25; 95%
CI = 1.32 to 3.84), along with APACHE II score (P = 0.016) and admission ALT (P = 0.0001).
Conclusions: Concurrent statin therapy does not appear to protect against the development of new acute organ
failure in critically ill, ventilated patients. The lack of effect may be due to residual confounding, a relatively low
number of doses received, or an absence of true effect. Randomised controlled trials are needed to confirm a
protective effect.
Introduction
Many patients suffering from severe infections and early
sepsis - conditions associated with deterioration and the
development of acute organ failure - require mechanical
ventilation after intensive care unit (ICU) admission
[1-3]. Mechanical ventilation is associated with
ventilator-associated pneumonia and increases the risk
of developing other nonrespiratory organ failures [1]. In
this context, acute organ failure appears to occur mostly
during the first 10 days after admission and is associated
with an increased risk of death [1,3,4]. Because many
mediator-targeting treatments for established severe sep-
sis have failed in randomised trials, an incentive exists to
prevent the onset of acute organ failure [5].
A candidate therapy to prevent acute organ failure is
the statin class of drugs, which may dampen the
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microbial invasion [6-10]. While numerous observational
studies support the notion of improved sepsis-related
outcome in those patients receiving long-term statin
therapy, it is not known whether such therapy protects
critically ill patients against the development of new
acute organ failure or the worsening of existing organ
dysfunction [11,12]. Furthermore, while statins are gen-
erally safe and well tolerated in the outpatient popula-
tion, their safety in the critically ill patient, particularly
with respect to liver function, is unknown [13].
Our objectives were to determine whether statin ther-
apy, as administered by clinicians to a cohort of
mechanically ventilated patients without nonrespiratory
organ failure within 24 hours of ICU admission,
(1) reduces the incidence of a composite endpoint of
new nonrespiratory organ failure or the worsening of
existing respiratory dysfunction during the first 15 days
of admission, and (2) is associated with liver impairment
as determined by changes in bilirubin and alanine trans-
ferase (ALT). We hypothesised that statin therapy does
not worsen liver function in this high-risk, clinically
important population and protects them against new
acute organ failure.
Materials and methods
Study design and setting
We performed a retrospective cohort study in which all
patients (regardless of diagnosis) receiving mechanical
ventilation but without nonrespiratory failure within
24 hours of admission to the ICU were followed until
ICU discharge, for a maximum of 15 days [14]. During
the follow-up period we assessed organ function
(defined by the Sequential Organ Failure Assessment
(SOFA) score) and ALT levels daily [14].
The study was performed in a single, tertiary aca-
demic, medical-surgical ICU and included patients
admitted between June 2002 and May 2006. Data were
extracted from the Clinical Information System (Care-
Vue™;P h i l i p s ,A m s t e r d a m ,T h eN e t h e r l a n d s ) .T h e
Clinical Information System is used for all aspects of
patient management. All drug prescriptions are electro-
nic, and the system interfaces with the institution’s
laboratory database and all monitoring equipment and
thus stores all physiological, treatment and pharmacolo-
gical information related to the patient’s ICU stay.
Participants
All adult (> 16 years of age) patients requiring mechani-
cal ventilation on admission to the ICU were eligible.
We excluded those patients re-admitted to the ICU dur-
ing their current hospitalisation, patients with any non-
respiratory organ failure within 24 hours of admission
(defined by SOFA ≥3), and patients missing admission
data that precluded the determination of baseline organ
function.
Data collection and follow-up
Raw data were extracted from the Clinical Information
System and transferred to a relational database (Micro-
soft Access™; Microsoft, Seattle, WA, USA). The study
database was programmed to calculate the SOFA score.
Patients were followed until ICU discharge, for a max-
imum of 15 days, because previous data from a large
international study suggest that deterioration occurs
mostly during the first 10 days after admission [1]. Dur-
ing the follow-up period, physiological, biochemical and
treatment data were collected daily. The vital status at
ICU discharge and hospital discharge and the respective
lengths of stay were recorded.
Exposure and outcome definitions
The main exposure variable was statin therapy received
in the ICU during the follow-up period. Statin exposure
was defined as the documented administration of a pre-
scribed dose at any time during the 15-day follow-up
period.
The specific indications for the statin prescription
were unknown. The critical care pharmacists, however,
routinely contacted the patients’ healthcare providers
and families to elicit information regarding chronic
medications, including prior statin prescriptions. During
the study period it was ICU policy, monitored by the
critical care pharmacists, to continue statin therapy
when previously prescribed and to start a new prescrip-
tion for recognised indications (for example, an acute
coronary syndrome).
There were three outcomes of interest. Acute organ
failure was defined by either worsening respiratory func-
tion compared with admission (defined as achieving a
SOFA respiratory score of 3 or 4 in those with a lower
s c o r e( 0 ,1o r2 )o na d m i s s i o n ,o ra ni n c r e a s ei nS O F A
respiratory score to 4 for those with a baseline SOFA of
3) or new nonrespiratory organ failure (defined by a
SOFA score of 3 or 4 for any of the cardiovascular,
renal, hepatic, or haematological systems). Since all
patients were sedated we did not consider the neurolo-
gical element of SOFA in the analysis. The outcome of
liver impairment was defined either by new hepatic fail-
ure, (defined as hepatic SOFA ≥3) or by an increase of
bilirubin ≥1.5 times from baseline to a value ≥20 mmol/
l. We separately considered the outcome of maximum
ALT > 165 IU/l (three times the laboratory’s upper limit
of normal).
We were interested in measuring the effect of statin
administration on both the incidence of liver failure (as
defined by SOFA) and on more subtle changes in func-
tion. We therefore deliberately used conservative cut-off
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the null hypothesis of no harm.
Statistical methods
Data are presented as the mean (standard deviation),
median (interquartile range) or number (percentage) as
appropriate. Baseline differences between exposure
groups were compared using Student’s t test or the Wil-
coxon rank sum test for continuous variables and the
chi-square test or Fisher’s exact test for binary variables,
as appropriate. We report the proportion of patients
with missing values. In unadjusted analyses, we handled
missing data in the following manner. Values of biliru-
bin missing on some days were imputed on a value car-
ried forward or value carried backward basis. Bilirubin
(n =2 0 )a n dA L T( n = 21) values missing on all
patient-days were assumed to be normal, representing
the most conservative approach. To calculate the num-
ber of days of acute organ failure, liver impairment, and
A L T>1 6 5I U / l ,w ec o u n t e dt h en u m b e ro fd a y st h a t
each of these events occurred without requiring that
they be consecutive.
Statin patients were classified as unexposed during the
days preceding the administration of the first statin
dose, and as exposed thereafter. For the descriptive ana-
lyses, we report for the statin group the number of out-
come events that occurred before statin administration,
on the same day or after statin administration, and at
least 1 day after statin administration.
To investigate the effect of treatment duration we per-
formed post hoc analyses, comparing the outcome events
in patients who received at least seven statin doses with
nonstatin-exposed patients who were in the ICU for at
least 7 days.
We analysed the effect of statin administration on the
outcomes of interest using a generalised linear mixed
model with logit link function while accounting for
repeated measures using an autoregressive correlation
structure. Odds ratios (OR) with 95% confidence inter-
vals (CIs) are presented. The effect of statins was
adjusted for age, gender, admission APACHE II score,
baseline total SOFA score (excluding the neurological
component), and main admission category (as defined
by APACHE II score) [15]. For the generalised linear
mixed models we considered outcome events in the sta-
tin group if they occurred on the day of statin or after
statin administration.
We interpreted P ≤ 0.05 as statistically significant
using two-sided tests. We used SAS version 9.2 software
(SAS Institute, Cary, NC, USA) for all analyses. We
used a convenience sample size based on the data avail-
able for the chosen study period to calculate effect esti-
mates and confidence intervals.
Ethics
The present study was approved by the institutional
review board of Guy’s&S tT h o m a s ’ NHS Foundation
Trust, which waived the need for informed consent.
Results
Descriptive data
During the study period, 4,621 patients were admitted to
the ICU (see Figure 1). Of these, 3,135 patients were
excluded because they were not ventilated, had nonre-
spiratory organ failure, had already been admitted to the
ICU during the same hospitalisation or had missing
baseline data. We therefore included 1,397 patients in
t h ef i n a ls t u d yc o h o r t .T h ea d m i s s i o nc a t e g o r y ,a s
defined by APACHE II score, was missing in 45/1,397
(3.2%) patients while 17/1,397 (1.26%) patients were
categorised as metabolic. Because only one patient in
the metabolic category received a statin, the entire cate-
gory was excluded from the regression analyses.
Two hundred and nineteen patients received a median
of 3 (2, 8) statin doses (Table 1). Of these, 70 patients
(32.0%), 77 patients (35.2%), 27 patients (12.3%) and 17
patients (7.8%) were started on days 1, 2, 3 and 4,
respectively. The most common statin administered was
simvastatin (72.2%; median dose 20 mg, range 10 to
80 mg), followed by atorvastatin (20.9%) and pravastatin
(6.9%).
Patients receiving statins were older (67.4 vs. 55.5
years, P < 0.0001), less likely female (25.1% vs. 37.9%,
P = 0.0003) and had higher APACHE II scores (20.3 vs.
17.8, P < 0.0001) than the nonstatin patients. Admission
respiratory function was worse in the statin group (P <
0.0001), which had more prevalent respiratory failure
(SOFA 3 or 4) and less prevalent respiratory dysfunction
(SOFA 1 or 2).
The baseline total nonrespiratory SOFA score was
higher in the statin group due to the presence of higher
extreme values: median values were 1 (0, 2) for both
groups (P = 0.0005), but the mean was 1.49 (1.31) in the
statin group and 1.18 (1.28) in the nonstatin group (P =
0.001). At baseline, statin patients were 1.9 and 5.3
times more likely to have renal (P < 0.0001) and cardio-
vascular (P < 0.0001) failure, respectively, but there was
no difference in haematological failure (P = 0.54). There
was no difference in baseline hepatic SOFA score (P =
0.49), although the baseline ALT was statistically signifi-
cantly higher in the statin group (34 vs. 24 IU/l, P <
0.0001).
Unadjusted outcome data
Overall, 380 (27.2%) patients developed acute organ fail-
ure. Of these patients, 21 (1.5%) in the statin group
developed acute organ failure before a statin was
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oped acute organ failure on or after the day of first sta-
tin administration compared with 292 patients (24.8%)
in the nonstatin group (P = 0.0073) (Table 2). Further-
more, 52 (28.4%) statin patients developed acute organ
failure at least 1 day after the first statin administration
compared with 292 (24.8%) nonstatin patients (P =
0 . 2 9 ) .T h e r ew e r ea l s on od i f f e r e n c e si nt h et i m et o
organ failure (3 (3, 4) vs. 3 (2, 5) days in statin vs.
nonstatin groups; P = 0.63) or duration of organ failure
(2 (1, 5) days in both groups; P = 0.77).
In total, 117 (8.4%) patients developed liver impair-
m e n t .O ft h e s e ,f i v ep a t i e n t s( 0 . 4 % )i nt h es t a t i ng r o u p
developed liver impairment before a statin was adminis-
tered. There were no differences observed in statin
patients who developed liver impairment on or after the
first stain administration (10.8% vs. 7.7%, P = 0.11), or
in statin patients who developed liver impairment at
Figure 1 Flow diagram of patients meeting the eligibility criteria. ICU, intensive care unit.
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7.6%, P = 0.34). Again, no differences were seen in
the time to liver impairment (4 (3, 6) vs. 5 (3, 8) days;
P = 0.46) or duration of liver impairment (1 (1, 4) vs.
2 (1, 3) days; P = 0.84).
At baseline, 84 patients had an ALT above the a priori
defined value of 165 IU/l that defined an outcome, and
were therefore not included in the ALT analysis. In the
remainder, the maximum ALT was 33 (18, 69) and 50
(28, 110) IU/l in the nonstatin and statin groups, respec-
tively. The ALT rose above 165 IU/l in 77 (5.9%)
patients, and occurred more frequently in statin patients
(11.6% considering events on or after the day of first
statin administration vs. 4.8%, P = 0.0002). Similarly, a
Table 1 Baseline characteristics
Variable Overall (n = 1,397) No statin exposure (n = 1,178) Statin exposed (n = 219) P value
Age (years) 57.4 (18.4) 55.5 (18.9) 67.4 (10.3) < 0.0001
APACHE II score 18.2 (6.8) 17.8 (6.9)
a 20.3 (6.0) < 0.0001
Female 501 (35.9%) 446 (37.9%) 55 (25.11%) 0.0003
Reason for admission
b < 0.0001
Infection 320 (22.9%) 269 (22.9%) 51 (23.3%)
Sepsis/septic shock 44 (3.2%) 39 (3.3%) 5 (2.3%)
Cardiac failure 31 (2.2%) 16 (1.4%) 15 (6.9%)
Haemorrhage 48 (3.4%) 46 (3.9%) 2 (0.9%)
Postoperative ventilation (planned) 176 (12.6%) 147 (12.5%) 29 (13.2%)
Postoperative ventilation (unplanned) 149 (10.7%) 112 (9.5%) 37 (16.9%)
Other
c 628 (45.0%) 548 (46.6%) 80 (36.5%)
Number of statin doses received 3 (2, 8)
Main admission category
d < 0.0001
Cardiovascular 464 (34.3%) 347 (30.5%) 117 (54.4%)
Gastrointestinal 118 (8.7%) 110 (9.7%) 8 (3.7%)
Metabolic 17 (1.3%) 16 (1.4%) 1 (0.5%)
Neurological 302 (22.3%) 286 (25.2%) 16 (7.4%)
Respiratory 451 (33.4%) 378 (33.2%) 73 (33.95%)
Admission source < 0.0001
Emergency room 369 (26.4%) 326 (27.7%) 43 (19.6%)
Hospital ward 221 (15.8%) 175 (14.9%) 46 (21%)
Another hospital 294(21.05%) 263 (22.3%) 31 (14.2%)
Operating room 377(26.99%) 310 (26.3%) 67 (30.6%)
High dependency ward 125 (8.95%) 98 (8.3%) 27 (12.3%)
Other 11 (0.79%) 6 (0.51%) 5 (2.3%)
Baseline biochemistry
Bilirubin (mmol/l) 17 (12, 25) 17 (12, 26)
e 17 (12, 23) 0.31
ALT (IU/l) 25 (15, 48.5) 24 (15, 46)
f 34 (18, 64) < 0.0001
Baseline SOFA
Total 3 (2, 4) 3 (2, 4) 4 (3, 5) < 0.0001
Median total nonrespiratory 1 (0, 2) 1 (0, 2) 1 (0, 2) 0.0005
Mean total nonrespiratory 1.23 ± 1.29 1.18 ± 1.28 1.49 ± 1.31 0.001
Respiratory: < 0.0001
0 70 (5.01%) 62 (5.3%) 8 (3.6%)
1 or 2 973 (69.7%) 843 (71.6%) 130 (59.4%)
3 or 4 354 (25.3%) 273 (23.2%) 81 (37.0%)
Hepatic 1 or 2 591 (42.3%) 503 (42.7%) 88 (40.2%) 0.49
Renal 1 or 2 328 (23.5%) 243 (20.6%) 85 (38.8%) < 0.0001
Haematological 1 or 2 341 (24.4%) 284 (24.1%) 57 (26.0%) 0.54
Cardiovascular 1 or 2 28 (2%) 14 (1.2%) 14 (6.4%) < 0.0001
Data expressed as mean ± standard deviation, median (interquartile range), or number (percentage). ALT, alanine transferase; APACHE, Acute Physiology and
Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment.
aData missing for 16 patients.
bData missing for one patient.
cInclude trauma (n = 44,
3.2%), overdose (n = 96, 6.9%), seizures (n = 84, 6.0%), post-arrest (n = 117, 8.4%) and abdominal obstruction or perforation (n = 54, 3.9%).
dData missing for 41
patients in the nonstatin group and four patients in the statin group.
eData missing for 20 patients.
fData missing for 21 patients.
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statin group when outcomes at least 1 day after the first
statin administration were considered (11.2% vs. 4.8%,
P = 0.0005). The timing of onset (8 (5, 12) vs. 6 (4, 11)
days after ICU admission, P = 0.35) and the duration of
the ALT rise (3 (1, 4) vs. 2 (1, 4) days, P = 0.66) were
similar in statin and nonstatin patients.
The overall lengths of ICU and hospital stays were 5
(3, 10) and 15 (8, 33) days, respectively. Patients receiv-
ing statins stayed longer in the ICU (by 3 days, P <
0.0001) and in the hospital (by 7 days, P < 0.0001).
Overall mortality in the ICU (12.7%) and hospital
(19.3%) was similar in statin and nonstatin patients (P =
0.96 and P = 0.21, respectively).
Regression analyses
In univariable analysis, statin exposure, increasing age,
higher admission APACHE II and admission SOFA scores,
and APACHE II admission category were associated with
acute organ failure (Table 3). After covariate adjustment,
the effect of statin administration was nonsignificant
(OR = 1.22; 95% CI = 0.92 to 1.62; P = 0.17); only the
APACHE II score (OR = 1.05 per point; 95% CI = 1.03 to
1.07; P< 0.0001) and APACHE II admission category (P <
0.0001) were significantly associated with acute organ fail-
ure. Relative to the APACHE II respiratory admission
category, the cardiovascular category was associated with a
higher risk of acute organ failure (OR = 1.34; 95% CI =
1.06 to 1.69; P =0 . 0 1 5 ) ,w h i l et h en e urological category
was associated with a lower risk (OR = 0.48; 95% CI =
0.33 to 0.71; P = 0.0002). Duration of treatment of at least
7 days was not associated with acute organ failure (n =
437; OR = 0.81; 95% CI = 0.53 to 1.23; P = 0.33).
In univariable analysis, statin exposure was not asso-
ciated with liver impairment (OR = 1.41; 95% CI = 0.89
to 2.24; P = 0.14; Table 4). While higher APACHE II
and baseline SOFA scores and the APACHE II admis-
sion category were associated with an increased risk of
liver impairment, female gender and lesser degrees of
hepatic dysfunction (hepatic SOFA score = 1) appeared
to be protective. After covariate adjustment, statin expo-
sure was not associated with liver impairment (OR =
1.08; 95% CI = 0.66 to 1.77; P = 0.75). Increasing
APACHE II score (OR = 1.05; 95% CI = 1.02 to 1.08;
P = 0.0007) and total nonhepatic SOFA score (OR =
1.29; 95% CI = 1.11 to 1.50; P < 0.0009) were strongly
associated with liver impairment. Patients with mild
hepatic dysfunction (SOFA score = 1) had one-half the
odds of developing liver impairment compared with
those with no dysfunction (OR = 0.49; 95% CI = 0.30 to
0.79; P = 0.0032). Female patients were less likely to
develop liver impairment (OR = 0.65; 95% CI = 0.42 to
99; P = 0.043). Treatment duration of at least 7 days
was not associated with an increased risk of liver
impairment (n = 437; OR = 0.54; 95% CI = 0.24 to 1.20;
P = 0.13).
Table 2 Unadjusted outcome data
Variable Overall (n = 1397) Nonstatin group (n = 1,178) Statin group (n = 219) P value
Organ failure
On or after day of first statin administration 359/1,376 (26.1%) 292/1,178 (24.8%) 67/198 (33.8%) 0.007
At least 1 day after first statin administration 344/1,361 (25.3%) 292/1,178 (24.8%) 52/183 (28.4%) 0.29
Days to organ failure 3 (2, 5) (n = 359) 3 (2, 5) (n = 292) 3 (3, 4) (n = 67) 0.63
Duration of organ failure
a 2 (1, 5) (n = 359) 2 (1, 5) (n = 292) 2 (1, 5) (n = 67) 0.77
Safety
Hepatic failure
b 112/1,392 (8.0%) 89/1,178 (7.6%) 23/214 (10.8%) 0.11
Days to hepatic failure 4 (3,8) (n = 112) 5 (3, 8) (n = 89) 4 (3, 6) (n = 23) 0.46
Duration of hepatic failure 1.5 (1, 3) (n = 112) 2 (1, 3) (n = 89) 1 (1, 4) (n = 23) 0.84
ALT > 165 IU/l
c 77/1,313 (5.9%) 54/1,115 (4.8%) 23/198 (11.6%) 0.0002
Days to ALT > 165 IU/l 7 (4, 11) (n = 77) 6 (4, 11) (n = 54) 8 (5, 12) (n = 23) 0.35
Duration of ALT > 165 IU/l 3 (1, 4) (n = 77) 2 (1, 4) (n = 54) 3 (1, 4) (n = 23) 0.66
Maximum ALT 35 (19, 73) (n = 1,292) 33 (18, 69) (n = 1,094) 50 (28, 110) (n = 198) < 0.0001
Other outcomes
ICU mortality 177/1,397 (12.7%) 149/1,178 (12.7%) 28/219 (12.8%) 0.96
Hospital mortality 270/1,397 (19.3%) 221/1,178 (18.8%) 49/219 (22.4%) 0.21
ICU length of stay 5 (3, 10) (n = 1,397) 4 (3, 9) (n = 1,178) 7 (4, 15) (n = 219) < 0.0001
Hospital length of stay 15 (8, 33) (n = 1,397) 14 (7, 31) (n = 1,178) 21 (12, 43) (n = 219) < 0.0001
Data expressed as mean ± standard deviation, median (interquartile range), or number (percentage). ALT, alanine transferase; ICU, intensive care unit.
aIncludes
four patients in the statin group who had a Sequential Organ Failure Assessment (SOFA) score (hepatic) ≥3 on the day of first statin administration.
bNew hepatic
failure on the day of or after the first day of statin administration (defined as hepatic SOFA score ≥3) or an increase of bilirubin by ≥1.5 times from baseline to a
value ≥20 mmol/l. Missing bilirubin values were assumed to be normal.
cExcludes those in statin group with ALT > 165 IU/l at baseline or occurring before the
first statin administration. Missing ALT values were assumed to be normal.
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exposure (adjusted OR = 2.25; 95% CI = 1.32 to 3.84;
P = 0.003), APACHE II score (OR = 1.04; 95% CI =
1.01 to 1.08; P = 0.016) and admission ALT (OR = 1.11;
95% CI = 1.05 to 1.18; P = 0.0001) were strongly asso-
ciated with a rise in ALT above 165 IU/l. Statin expo-
sure remained associated with an ALT increase in those
who received at least seven doses (n = 407; OR = 2.39,
95% CI = 1.25 to 4.59; P = 0.009).
Discussion
The major finding from our single-centre retrospective
cohort study of mechanically ventilated patients without
baseline extrapulmonary organ failure is that concurrent
Table 3 Predictors of acute organ failure occurring on or after the first day of statin administration
Variable (n = 1,319)
a Univariable analyses Multivariable analyses
Odds ratio 95% CI P value Odds ratio 95% CI P value
Statin versus no statin 1.40 1.06 to 1.84 0.016 1.22 0.92 to 1.62 0.17
Age
b 1.008 1.00 to 1.01 0.007 1.00 0.99 to 1.01 0.68
Admission APACHE II score
b 1.054 1.04 to 1.07 < 0.0001 1.05 1.03 to 1.07 < 0.0001
APACHE II admission category (reference level: respiratory) < 0.0001 < 0.0001
Cardiovascular 1.39 1.11 to 1.75 0.005 1.34 1.06 to 1.69 0.015
Gastrointestinal 0.91 0.61 to 1.36 0.64 0.97 0.65 to 1.45 0.89
Neurological 0.45 0.31 to 0.66 < 0.0001 0.48 0.33 to 0.71 0.0002
Gender (female) 0.98 0.79 to 1.22 0.85 0.95 0.76 to 1.18 0.65
Total baseline SOFA
b 1.097 1.03 to 1.17 0.005 1.002 0.94 to 1.07 0.95
APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; SOFA, Sequential Organ Failure Assessment.
aSeventy-eight patients were
excluded from the model: 61 patients with missing data on at least one of the variables included in the model, and 17 patients who have the APACHE II
admission category of metabolic, of whom only one was in the statin group.
bOdds ratios per one-unit increase.
Table 4 Predictors of liver impairment and ALT > 165 IU/l occurring on or after first day of statin administration
Variable Univariable analyses Multivariable analyses
Odds ratio 95% CI P value Odds ratio 95% CI P value
Liver impairment (n = 1,319)
a
Statin versus no statin 1.41 0.89 to 2.24 0.14 1.08 0.66 to 1.77 0.75
Age
b 1.005 0.99 to 1.02 0.36 0.99 0.98 to 1.004 0.21
Admission APACHE II score
b 1.06 1.03 to 1.09 < 0.0001 1.05 1.02 to 1.08 0.0007
APACHE II admission category (reference level: respiratory) 0.017 0.062
Cardiovascular 1.57 1.04 to 2.39 0.033 1.43 0.93 to 2.19 0.099
Gastrointestinal 1.46 0.76 to 2.80 0.25 1.67 0.86 to 3.25 0.13
Neurological 0.58 0.28 to 1.19 0.14 0.62 0.30 to 1.30 0.21
Gender (female) 0.62 0.41 to 0.94 0.028 0.65 0.42 to 0.99 0.043
Baseline hepatic SOFA 0.065 0.011
1 versus 0 0.58 0.36 to 0.92 0.02 0.49 0.30 to 0.79 0.0032
2 versus 0 0.85 0.49 to 1.46 0.56 0.67 0.38 to 1.18 0.17
Total baseline nonhepatic SOFA
b 1.36 1.19 to 1.55 < 0.0001 1.29 1.11 to 1.50 0.0009
ALT (n = 1,229)
c
Statin versus no statin 2.22 1.37 to 3.60 0.001 2.25 1.32 to 3.84 0.003
Age
b 1.00 0.98 to 1.01 0.46 0.99 0.97 to 1.002 0.091
Admission APACHE II score
b 1.05 1.01 to 1.08 0.005 1.04 1.01 to 1.08 0.016
APACHE II admission category (reference level: respiratory) 0.054 0.12
Cardiovascular 1.47 0.89 to 2.41 0.13 1.16 0.70 to 1.94 0.57
Gastrointestinal 0.30 0.072 to 1.25 0.098 0.40 0.094 to 1.70 0.21
Neurological 1.63 0.90 to 2.94 0.11 1.80 0.97 to 3.34 0.063
Gender (female) 0.77 0.48 to 1.22 0.26 0.90 0.56 to 1.45 0.67
Baseline ALT
d 1.14 1.08 to 1.20 < 0.0001 1.11 1.05 to 1.18 0.0001
Total baseline SOFA
b 1.10 0.96 to 1.26 0.17 1.08 0.94 to 1.25 0.26
Predictors of liver impairment and alanine transferase (ALT) > 165 IU/l occurring on or after the first day of statin administration. APACHE, Acute Physiology and
Chronic Health Evaluation; CI, confidence interval; SOFA, Sequential Organ Failure Assessment.
aSeventy-eight patients were excluded from the model: 61 patients
with missing data on at least one of the variables included in the model, and 17 patients with the APACHE II admission category of metabolic, of whom only one
was in the statin group.
bOdds ratios per one-unit increase.
cA total of 168 patients were excluded from the model: 77 patients with baseline ALT > 165 IU/l, 75
with missing data for at least one of the variables included in the model, and 16 patients with the APACHE II admission category of metabolic, of whom only
one was in the statin group.
dOdds ratio per 10-unit increase.
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Page 7 of 10statin therapy did not reduce the incidence of new acute
organ failure. Furthermore, while statin therapy was
associated with a statistically significant but clinically
small rise in the ALT level, it was not associated with
liver impairment as defined by changes in bilirubin. Sta-
tin-exposed patients were on average older, predomi-
nantly male and were sicker (as reflected by higher
APACHE II and total SOFA scores) on admission. The
overall incidence of acute organ failure in this cohort
was 25.3%, took a median 3 days to develop and lasted
for a median of 2 days, with no differences between sta-
tin and nonstatin groups.
The present study is the first designed specifically to
investigate the effect of concurrent statin therapy on the
incidence of acute organ failure in ventilated, critically
ill patients. In contrast, the existing observational litera-
ture suggests that statin therapy protects against sepsis-
related morbidity and mortality [11,12]. These studies
have focused on pre-ICU admission chronic statin use,
different populations and outcomes, and have used
widely varying selection criteria. Studies exploring statin
effects in the ICU have predominantly included patients
with established severe sepsis.
Several smaller observational studies have investigated
statin administration in the ICU and found variable
effects on clinical outcomes. Fernandez and colleagues
examined 438 patients at high risk of ICU-acquired
infection, defined as those receiving mechanical ventila-
tion for 96 hours [16]. Those who continued previous
statin therapy while in the ICU developed statistically
nonsignificantly fewer infections than statin nonusers,
but were more likely to die in hospital. Schmidt and col-
leagues found lower mortality in 40 ICU patients with
multiple organ dysfunction syndrome receiving statin
therapy compared with 80 age- and sex-matched multi-
ple organ dysfunction syndrome patients not receiving
statins [17]. Dobesh and colleagues enrolled 188 patients
with established severe sepsis (statin exposed, n = 60)
and found a significantly reduced risk of hospital mor-
tality [18]. In contrast, de Saint Martin and colleagues
found no differences between statin-exposed and nonex-
posed patients (n = 921) older than 40 years of age
admitted with fever in multiple outcomes (mortality,
length of hospitalisation, ICU admission, and admission
to convalescent homes) [19]. Finally, Kor and colleagues
measured the development and progression of pulmon-
ary and nonpulmonary organ failure for 178 patients
with acute lung injury/acute respiratory distress syn-
drome and found no statin effects on the PaO2/FiO2
ratio and total SOFA score in univariable analyses [20].
Inferences from all these studies are subject to con-
founding by indication.
The present study has several strengths. First, it is the
largest study specifically designed to investigate the
effect of concurrent statin therapy on the incidence of
acute organ failure in mechanically ventilated patients
without extrapulmonary organ failure, and is the only
study reporting effects on bilirubin and ALT values. Sec-
ond, the study population is well-defined and clinically
important, because the incidence of new acute organ
failure is high and potentially preventable. Third, expo-
sure was based on statin administration rather than pre-
scription. Lastly, the statistical models appropriately
account for repeated measures of daily assessment organ
function per patient.
Our study shares several limitations of the existing
observational literature. First, although we conducted
careful multivariable analyses, we cannot eliminate the
possibility of residual confounding. In particular, we did
not know the clinical indications for statin treatment,
but used the APACHE II admission category, which
includes a cardiovascular category, as an adjustment
variable. In contrast, information bias seems less likely
since only 2.9% of eligible patients were excluded and
4.4% were excluded from regression models due to
missing data. Second, we did not have data on pread-
mission statin treatment, leaving the possibility that a
significant proportion of those patients deemed unex-
posed may have been prior users. During the study
period our unit policy was to continue previous statin
therapy, and dedicated ICU pharmacists routinely inter-
viewed patients, relatives and the patients’ general
practitioners to obtain information on all chronic medi-
cations. If acute withdrawal of statin therapy is harmful,
the effect of this misclassification bias would tend to
diminish any findings of benefit [21]. Importantly,
recently published data from a randomised controlled
trial in which critically ill patients were randomised to
continue or stop prior atorvastatin treatment showed no
outcome differences between the exposure groups [22].
Third, we cannot confirm whether statins were actually
absorbed after enteral administration. Recent data do
show, however, that enteral atorvastatin is well absorbed
[23]. Fourth, we were unable to study the association
between statin therapy and muscle complications
because creatinine kinase is not routinely collected for
clinical purposes and the data were therefore not avail-
able for analyses. Fifth, we may have underestimated the
association between statin administration and outcomes
due to the effect of immortal time bias [24]. Finally, the
study was performed using data obtained from a single
academic institution and may not be generalisable to
other study populations.
The reasons for the apparent failure to demonstrate a
benefit are unclear, but include the potential sources of
error inherent in all observational methodologies, the
relatively low number of doses received (median of
three), or the absence of any beneficial biological effect.
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Page 8 of 10Although the subgroup analyses also do not suggest a
beneficial effect, the results must be interpreted carefully
given that the analyses were post hoc and the study was
not designed with these analyses in mind. Craig and col-
leagues, however, recently showed that treatment with
simvastatin appears to be safe and may be associated
with an improvement in organ dysfunction in acute
lung injury [25]. Lastly, although we previously estab-
lished biological plausibility and proposed biological
pathways modulated by statin therapy, it is possible that
these pathways are not the ones involved in the develop-
ment of acute organ failure [7,9].
Conclusions
Based on these results, concurrent statin therapy does
not appear to protect against the development of new
acute organ failure in critically ill, ventilated patients,
but it does not appear to cause liver failure. While
therapy was associated with a rise in ALT, the clinical
relevance of this finding is unclear. Given the limited
inferences from observational data and persistent biolo-
gical rationale for the benefit of statin administration in
this population at high risk of organ failure, sufficiently
powered randomised controlled trials are needed.
Key messages
￿ Many patients with early sepsis develop acute
organ failure, and no mediator-targeting treatments
able to prevent this progression are available.
￿ Current observational data suggest that statins may
prevent sepsis-related morbidity and mortality.
￿ In the largest study specifically designed to test
whether statins prevent the onset of new acute
organ failure in ventilated ICU patients, we found no
evidence of protection.
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